By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

24 coronavirus projects for vaccines and therapeutics

FFG ad for Corona Research call © FFG

The funds are designed to accelerate research being conducted to fight the coronavirus. 24 projects were selected in the first application round. Two of the 24 projects involve clinical studies on the development of vaccines, whereas eight projects focus on developing therapeutic agents. Twelve initiatives aim at developing diagnostic products, and two projects target infection prevention and control.

Vaccine development and development of therapeutics

The companies Themis Bioscience GmbH, Baxalta Innovations GmbH, Apeiron, AOP Orphan Pharmaceuticals AG, Cyprumed GmbH, Marinomed Biotech AG, Apeptico, Panoptes Pharma GesmbH and AIT Angewandte Informationstechnik operate in the field of "vaccine development".

Development of diagnostic products

The following firms focus on the "development of diagnostic products": Qualizyme Diagnostics, Attoquant Diagnostics GmbH, Viravaxx AG, Dr. Gernot Walder GmbH, Genspeed Biotech GmbH, Labdia Labordiagnostik, Lexogen GmbH, Next Generation Sequencing (NGS), Novogenia GmbH, Pharmgenetix GmbH, BioTreaT GmbH, SteadySense GmbH and RPD Rapid Product Development GmbH.

Find more details on the project (in German).

Read more about the current support for your company in times of Corona.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Life Sciences Wien - Ein Markt mit vielen Chancen

    28.01.2021, 10:00 - 11:30 (CET), Online Conference

  • Meet us @ HTH Styria!

    28.1.2021, 10:00 - 16:15 (CET) , Online Conference

Austria Map

Find the perfect location for your company

Reliability and expertise in the country and in the company are the convincing factors in selecting a business location. We can be justifiably proud but can still become even more attractive. This is something Austria should increasingly work on in the future!

Pfizer

Logo
More testimonials

news from the business location Austria

Austrian government creates investment premium for investors

The economic and financial consequences of the COVID-19 crisis pose major challenges to companies. In order to strengthen the Austrian business location, the Austrian Federal Government has resolved upon a new investment promotion program for companies with a total volume of EUR 3 billion, which will be further increased, if necessary.

Support measures for companies affected by COVID-19

To stimulate the economy, either new programs may be established as a result of the draft law or existing support programs (e.g. aws, ÖHT) will be expanded. All measures introduced are intended to be applicable immediately and will be in force until the end of 2020. The measures currently introduced include the following areas:

More news All blog posts